Thompson Siegel & Walmsley LLC Purchases New Holdings in Rocket Pharmaceuticals, Inc. (NASDAQ:RCKT)

Thompson Siegel & Walmsley LLC purchased a new stake in Rocket Pharmaceuticals, Inc. (NASDAQ:RCKT) in the 4th quarter, HoldingsChannel reports. The institutional investor purchased 12,747 shares of the biotechnology company’s stock, valued at approximately $160,000.

Several other institutional investors have also made changes to their positions in RCKT. Wellington Management Group LLP boosted its stake in shares of Rocket Pharmaceuticals by 22.8% in the third quarter. Wellington Management Group LLP now owns 11,242,144 shares of the biotechnology company’s stock valued at $207,642,000 after buying an additional 2,086,424 shares during the period. State Street Corp boosted its stake in shares of Rocket Pharmaceuticals by 11.6% in the third quarter. State Street Corp now owns 3,102,022 shares of the biotechnology company’s stock valued at $57,294,000 after buying an additional 322,156 shares during the period. Maverick Capital Ltd. lifted its stake in Rocket Pharmaceuticals by 4.8% during the third quarter. Maverick Capital Ltd. now owns 4,118,672 shares of the biotechnology company’s stock worth $76,072,000 after purchasing an additional 190,360 shares during the last quarter. Westfield Capital Management Co. LP lifted its stake in Rocket Pharmaceuticals by 3.8% during the third quarter. Westfield Capital Management Co. LP now owns 4,493,833 shares of the biotechnology company’s stock worth $83,001,000 after purchasing an additional 165,911 shares during the last quarter. Finally, Sovran Advisors LLC bought a new stake in Rocket Pharmaceuticals during the fourth quarter worth $1,895,000. 98.39% of the stock is currently owned by institutional investors.

Analysts Set New Price Targets

Several research firms have weighed in on RCKT. Canaccord Genuity Group cut their target price on Rocket Pharmaceuticals from $39.00 to $36.00 and set a “buy” rating for the company in a research note on Monday, March 3rd. Cantor Fitzgerald restated an “overweight” rating and set a $65.00 target price on shares of Rocket Pharmaceuticals in a research note on Tuesday, November 19th. Jefferies Financial Group began coverage on Rocket Pharmaceuticals in a research note on Wednesday, December 18th. They set a “buy” rating and a $29.00 target price for the company. Chardan Capital cut their target price on Rocket Pharmaceuticals from $62.00 to $54.00 and set a “buy” rating for the company in a research note on Friday, February 28th. Finally, Needham & Company LLC cut their target price on Rocket Pharmaceuticals from $52.00 to $42.00 and set a “buy” rating for the company in a research note on Friday, February 28th. One investment analyst has rated the stock with a hold rating and eleven have assigned a buy rating to the company. According to data from MarketBeat, the stock has a consensus rating of “Moderate Buy” and a consensus target price of $43.00.

Rocket Pharmaceuticals Stock Performance

NASDAQ RCKT opened at $8.76 on Friday. The company has a market capitalization of $934.08 million, a price-to-earnings ratio of -3.19 and a beta of 1.03. Rocket Pharmaceuticals, Inc. has a twelve month low of $8.06 and a twelve month high of $28.67. The stock has a fifty day simple moving average of $10.30 and a 200 day simple moving average of $14.08. The company has a quick ratio of 6.05, a current ratio of 6.05 and a debt-to-equity ratio of 0.06.

Rocket Pharmaceuticals (NASDAQ:RCKT) last posted its quarterly earnings data on Monday, March 3rd. The biotechnology company reported ($0.62) earnings per share for the quarter, beating analysts’ consensus estimates of ($0.68) by $0.06. Sell-side analysts expect that Rocket Pharmaceuticals, Inc. will post -2.83 EPS for the current year.

Rocket Pharmaceuticals Company Profile

Rocket Pharmaceuticals, Inc, together with its subsidiaries, operates as a late-stage biotechnology company that focuses on developing gene therapies for rare and devastating diseases. It has three clinical-stage ex vivo lentiviral vector programs for fanconi anemia, a genetic defect in the bone marrow that reduces production of blood cells or promotes the production of faulty blood cells; leukocyte adhesion deficiency-I, a genetic disorder that causes the immune system to malfunction; and pyruvate kinase deficiency, a rare red blood cell autosomal recessive disorder that results in chronic non-spherocytic hemolytic anemia.